A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare outcomes, costs and incremental cost-effectiveness of heroin detoxification performed in a specialist clinic and in general practice. DESIGN AND SETTING: Randomised controlled trial set in a specialist outpatient drug treatment centre and six office-based general practices in inner city Sydney, Australia. PARTICIPANTS: 115 people seeking treatment for heroin dependence, of whom 97 (84%) were reinterviewed at Day 8, and 78 (68%) at Day 91. INTERVENTIONS: Participants were randomly allocated to primary care or a specialist clinic, and received buprenorphine for 5 days for detoxification, then were offered either maintenance therapy with methadone or buprenorphine, relapse prevention with naltrexone, or counselling alone. MAIN OUTCOME MEASURES: Completion of detoxification, engagement in post-detoxification treatment, and heroin use assessed at Days 8 and 91. Costs relevant to providing treatment, including staff time, medication use and diagnostic procedures, with abstinence from heroin use on Day 8 as the primary outcome measure. RESULTS: There were no significant differences in the proportions completing detoxification (40/56 [71%] primary care v 46/59 [78%] clinic), participating in postwithdrawal treatment (28/56 [50%] primary care v 36/59 [61%] clinic), reporting no opiate use during the withdrawal period (13/56 [23%] primary care v 13/59 [22%] clinic), and in duration of postwithdrawal treatment by survival analysis. Most participants in both groups entered postwithdrawal buprenorphine maintenance. On an intention-to-treat basis, self-reported heroin use in the month before the Day 91 interview was significantly lower than at baseline (27 days/month at baseline, 14 days/month at Day 91; P < 0.001) and did not differ between groups. Buprenorphine detoxification in primary care was estimated to be $24 more expensive per patient than treatment at the clinic. The incremental cost-effectiveness ratio reveals that, in this context, it costs $20 to achieve a 1% improvement in outcome in primary care. CONCLUSIONS: Buprenorphine-assisted detoxification from heroin in specialist clinic and primary care settings had similar efficacy and cost-effectiveness. Buprenorphine treatment can be initiated safely in primary care settings by trained GPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Are detoxification programmes effective?
Mattick, R. P., & Hall, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90215-9 · Cited by 196
A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence
Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150
GP attitudes to managing drug‐ and alcohol‐dependent patients: a reluctant role
ABOUYANNI, G., STEVENS, L. J., HARRIS, M. F., WICKES, W. A., RAMAKRISHNA, S. S., TA, E., & KNOWLDEN, S. M. (2000) · Drug and Alcohol Review · doi:10.1080/713659318 · Cited by 59
Cited by
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585
Self-citationGuidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104010028 · Cited by 398
Buprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Exposure to opioid maintenance treatment reduces long‐term mortality
Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02090.x · Cited by 194
“The cut-off period of 7 days was selected as this is the approximate duration of physical heroin withdrawal symptoms [18] and the length of several commonly used out-patient heroin withdrawal regimens in use in Australia [19,20].”
MethodSelf-citation
Metadata
- Authors
- Gibson, A. E., Doran, C. M., Bell, J. R., Ryan, A., & Lintzeris, N.
- Venue
- Medical Journal of Australia
- Publisher
- AMPCo
- Published
- 2003-07
- Volume
- 179
- Issue
- 1
- Pages
- 38-42
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W2102408640
- Cited by
- 94
- References
- 4
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. https://app.cochat.ai/papers/10.5694/j.1326-5377.2003.tb05417.x
- The paper
- Gibson, A. E., Doran, C. M., Bell, J. R., Ryan, A., & Lintzeris, N. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2003.tb05417.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.